• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Silence Therapeutics Plc ADR (NQ: SLN )

    15.53 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 15.53
    Bid (Size) 8.010 (1)
    Ask (Size) 23.99 (1)
    Prev. Close 15.53
    Today's Range 15.53 - 15.53
    52wk Range 6.150 - 27.72
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Analyst Expectations For Silence Therapeutics's Future
    Via Benzinga
    SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024
    Silence Therapeutics just reported results for the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -16.28%
    -16.28%
    1 Month
    -28.56%
    -28.56%
    3 Month
    -29.41%
    -29.41%
    6 Month
    -32.68%
    -32.68%
    1 Year
    +82.92%
    +82.92%

    More News

    Read More
    Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
    From Silence Therapeutics plc
    Via Business Wire
    The 3 Best Gene Editing Stocks to Buy in August 2024
    Via InvestorPlace
    Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
    Via InvestorPlace
    The Analyst Landscape: 6 Takes On Silence Therapeutics
    Via Benzinga
    What 7 Analyst Ratings Have To Say About Silence Therapeutics
    Via Benzinga
    Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
    Via Benzinga
    Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
    From Silence Therapeutics plc
    Via Business Wire
    Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
    From Silence Therapeutics plc
    Via Business Wire
    Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
    From Silence Therapeutics plc
    Via Business Wire
    What 4 Analyst Ratings Have To Say About Silence Therapeutics
    Via Benzinga
    Silence Therapeutics to Present at Jefferies Global Healthcare Conference
    From Silence Therapeutics plc
    Via Business Wire
    SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024
    Via InvestorPlace
    Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
    From Silence Therapeutics plc
    Via Business Wire
    Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
    From Silence Therapeutics plc
    Via Business Wire
    Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
    From Silence Therapeutics plc
    Via Business Wire
    3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
    Via InvestorPlace
    Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
    From Silence Therapeutics plc
    Via Business Wire
    7 Biotech Stocks Ready to Ride the Sector’s Resurgence
    Via InvestorPlace
    These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
    Via Benzinga
    What's Going On With Silence Therapeutics Stock Today?
    Via Benzinga
    Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
    From Silence Therapeutics plc
    Via Business Wire
    Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
    From Silence Therapeutics plc
    Via Business Wire
    Earnings Scheduled For March 13, 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.